(CORT) Corcept Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.520m USD | Total Return: -42.1% in 12m
Medications, Treatments, Disorders, Drugs
Total Rating 34
Safety 86
Buy Signal -0.71
Biotechnology
Industry Rotation: +4.1
Industry Rotation: +4.1
Market Cap:
4.52B
Avg Turnover: 50.3M USD
Avg Turnover: 50.3M USD
ATR:
5.87%
Peers RS (IBD): 10.5
Peers RS (IBD): 10.5
Risk 5d forecast
Volatility63.9%
Rel. Tail Risk-23.0%
Reward TTM
Sharpe Ratio-0.26
Alpha-95.64
Character TTM
Beta1.495
Beta Downside3.765
Drawdowns 3y
Max DD71.85%
CAGR/Max DD0.33
EPS (Earnings per Share)
EPS CAGR: -46.72%
EPS Trend: -26.6%
EPS Trend: -26.6%
Last SUE: 1.59
Qual. Beats: 1
Qual. Beats: 1
Revenue
Rev. CAGR: 22.76%
Rev. Trend: 97.2%
Rev. Trend: 97.2%
Last SUE: -4.00
Qual. Beats: 0
Qual. Beats: 0
Warnings
Volatile
Tailwinds
No distinct edge detected
Description: CORT Corcept Therapeutics
Corcept Therapeutics is a biopharmaceutical company focused on developing treatments for severe endocrine, oncology, metabolic, and neurological disorders.
The company markets Korlym, an oral medication for hyperglycemia in adults with Cushings syndrome and type 2 diabetes or glucose intolerance, particularly when surgery is not an option. This product targets a niche market within the pharmaceutical sector, focusing on specific patient populations with complex conditions.
Corcept also has several drug candidates in development, including relacorilant for hypercortisolism, miricorilant for metabolic dysfunction-associated steatohepatitis (currently in Phase 1b trials), and a pipeline of selective cortisol modulators for Lou Gehrigs disease. The biopharmaceutical business model relies heavily on R&D and clinical trials, with significant investment required before product commercialization.
Further research on ValueRay can provide more in-depth analysis of Corcepts pipeline and market position.
- Korlym sales growth drives revenue
- Relacorilant clinical trial success impacts future revenue
- Research and development expenses affect profitability
- Regulatory approval for new drugs is critical
Piotroski VR‑10 (Strict)
5.0
| Net Income: 99.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.17 > 0.02 and ΔFCF/TA -6.36 > 1.0 |
| NWC/Revenue: 41.95% < 20% (prev 49.01%; Δ -7.06% < -1%) |
| CFO/TA 0.17 > 3% & CFO 142.0m > Net Income 99.1m |
| Net Debt (-366.0m) to EBITDA (57.1m): -6.41 < 3 |
| Current Ratio: 2.92 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.9m) vs 12m ago 1.18% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 90.79% > 50% (prev 80.31%; Δ 10.49% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
Altman Z''
9.04
| A: 0.38 (Total Current Assets 485.5m - Total Current Liabilities 166.1m) / Total Assets 836.7m |
| B: 0.77 (Retained Earnings 643.4m / Total Assets 836.7m) |
| C: 0.07 (EBIT TTM 55.2m / Avg Total Assets 838.6m) |
| D: 3.42 (Book Value of Equity 645.8m / Total Liabilities 188.8m) |
| Altman-Z'' Score: 9.04 = AAA |
Beneish M
-3.08
| DSRI: 0.91 (Receivables 59.8m/58.1m, Revenue 761.4m/675.0m) |
| GMI: 1.00 (GM 98.30% / 98.39%) |
| AQI: 0.96 (AQ_t 0.41 / AQ_t-1 0.43) |
| SGI: 1.13 (Revenue 761.4m / 675.0m) |
| TATA: -0.05 (NI 99.1m - CFO 142.0m) / TA 836.7m) |
| Beneish M-Score: -3.08 (Cap -4..+1) = AA |
What is the price of CORT shares?
As of April 10, 2026, the stock is trading at USD 42.25 with a total of 925,444 shares traded.
Over the past week, the price has changed by -0.56%, over one month by +24.30%, over three months by +12.67% and over the past year by -42.10%.
Over the past week, the price has changed by -0.56%, over one month by +24.30%, over three months by +12.67% and over the past year by -42.10%.
Is CORT a buy, sell or hold?
Corcept Therapeutics has received a consensus analysts rating of 4.50.
Therefore, it is recommended to buy CORT.
- StrongBuy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CORT price?
| Analysts Target Price | 67.4 | 59.5% |
Corcept Therapeutics (CORT) - Fundamental Data Overview
as of 06 April 2026
P/E Trailing = 51.8171 P/E Forward = 120.4819
P/S = 5.9362
P/B = 6.9854
P/EG = 0.813
Revenue TTM = 761.4m USD
EBIT TTM = 55.2m USD
EBITDA TTM = 57.1m USD
Long Term Debt = 6.11m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.08m USD (from shortTermDebt, last quarter)
Debt = 6.11m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -366.0m USD (recalculated: Debt 6.11m - CCE 372.2m)
Enterprise Value = 4.15b USD (4.52b + Debt 6.11m - CCE 372.2m)
Interest Coverage Ratio = unknown (Ebit TTM 55.2m / Interest Expense TTM 0.0)
EV/FCF = 29.30x (Enterprise Value 4.15b / FCF TTM 141.8m)
FCF Yield = 3.41% (FCF TTM 141.8m / Enterprise Value 4.15b)
FCF Margin = 18.62% (FCF TTM 141.8m / Revenue TTM 761.4m)
Net Margin = 13.01% (Net Income TTM 99.1m / Revenue TTM 761.4m)
Gross Margin = unknown ((Revenue TTM 761.4m - Cost of Revenue TTM 13.0m) / Revenue TTM)
Tobins Q-Ratio = 4.96 (Enterprise Value 4.15b / Total Assets 836.7m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.11m)
Taxrate = 21.0% (US default 21%)
NOPAT = 43.6m (EBIT 55.2m * (1 - 21.00%))
Current Ratio = 2.92 (Total Current Assets 485.5m / Total Current Liabilities 166.1m)
Debt / Equity = 0.01 (Debt 6.11m / totalStockholderEquity, last quarter 647.8m)
Debt / EBITDA = -6.41 (Net Debt -366.0m / EBITDA 57.1m)
Debt / FCF = -2.58 (Net Debt -366.0m / FCF TTM 141.8m)
Total Stockholder Equity = 649.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.82% (Net Income 99.1m / Total Assets 836.7m)
RoE = 15.25% (Net Income TTM 99.1m / Total Stockholder Equity 649.7m)
RoCE = 8.42% (EBIT 55.2m / Capital Employed (Equity 649.7m + L.T.Debt 6.11m))
RoIC = 6.72% (NOPAT 43.6m / Invested Capital 649.7m)
WACC = 11.22% (E(4.52b)/V(4.53b) * Re(11.24%) + D(6.11m)/V(4.53b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.97%
[DCF] Terminal Value 69.02% ; FCFF base≈163.4m ; Y1≈176.8m ; Y5≈219.6m
[DCF] Fair Price = 25.45 (EV 2.34b - Net Debt -366.0m = Equity 2.71b / Shares 106.4m; r=11.22% [WACC]; 5y FCF grow 9.27% → 3.0% )
EPS Correlation: -26.56 | EPS CAGR: -46.72% | SUE: 1.59 | # QB: 1
Revenue Correlation: 97.17 | Revenue CAGR: 22.76% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.05 | Chg7d=+0.010 | Chg30d=+0.010 | Revisions Net=+1 | Analysts=5
EPS current Year (2026-12-31): EPS=0.41 | Chg7d=+0.022 | Chg30d=+0.022 | Revisions Net=-1 | Growth EPS=-50.5% | Growth Revenue=+22.8%
EPS next Year (2027-12-31): EPS=1.61 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=+296.1% | Growth Revenue=+27.8%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 9.3% (Discount Rate 11.2% - Earnings Yield 1.9%)
[Growth] Growth Spread = +5.0% (Analyst 14.3% - Implied 9.3%)
External Resources